Cellebrite DI (NASDAQ:CLBT) PT Increased to $18.00

Cellebrite DI (NASDAQ:CLBT – Get Free Report) had its price target raised by research analysts at Deutsche Bank Aktiengesellschaft from $15.00 to $18.00 in a note issued to investors on Friday, Benzinga reports. The firm currently has a “buy” rating on the stock. Deutsche Bank Aktiengesellschaft’s price target suggests a potential upside of 9.49% to the stock’s current price.

CLBT has been the subject of several other reports. Lake Street Capital raised their price target on Cellebrite DI from $13.50 to $17.00 and gave the company a “buy” rating in a report on Friday. Needham & Company LLC raised their price target on Cellebrite DI from $14.00 to $17.00 and gave the stock a “buy” rating in a research report on Friday. JPMorgan Chase & Co. raised their price target on shares of Cellebrite DI from $14.00 to $15.00 and gave the company an “overweight” rating in a research report on Wednesday. Bank of America raised their price target on shares of Cellebrite DI from $13.00 to $17.00 and gave the stock a “buy” rating in a report on Friday. Finally, Craig Hallum raised their price target on shares of Cellebrite DI from $16.00 to $20.00 and gave the company a “buy” rating in a report on Friday. Seven analysts have rated the stock with a “buy” rating. According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $17.33.

Check out our latest analysis on Cellebrite DI

Cellebrite DI Price-performance

CLBT shares opened at $16.44 on Friday. The stock has a market cap of $3.39 billion, a price/earnings ratio of -28.34, a price/earnings/growth ratio of 1.90, and a beta of 1.50. Cellebrite DI has a one-year low of $6.36 and a one-year high of $16.59. The company has a 50-day moving average price of $12.66 and a 200-day moving average price of $11.56.

Cellebrite DI (NASDAQ: CLBT – Get Free Report) last released its earnings results on Thursday, August 15th. The company reported $0.10 EPS for the quarter, topping analysts’ consensus estimates of $0.08 by $0.02. Cellebrite DI had a positive return on equity of 417.94% and a negative net margin of 32.57%. The company had revenue of $95.70 million during the quarter, compared to analyst estimates of $91.94 million. During the same quarter in the prior year, the company earned $0.05 EPS. Cellebrite DI’s revenue increased 24.8% year over year. As a group, analysts expect Cellebrite DI to post 0.34 EPS for the current year.

Institutional inflow and outflow

Several hedge funds have recently bought and sold shares of CLBT. Point72 Asia Singapore Pte. Ltd. increased its position in shares of Cellebrite DI by 59.6% in the second quarter. Point72 Asia Singapore Pte. Ltd. now owns 2,724 shares of the company’s stock worth $33,000 after acquiring an additional 1,017 shares in the last quarter. Scalar Gauge Management LLC increased its stake in Cellebrite DI by 15.2% in the second quarter. Scalar Gauge Management LLC now owns 453,554 shares of the company’s stock worth $5,420,000 after purchasing an additional 60,000 shares during the period. Apis Capital Advisors LLC increased its stake in Cellebrite DI by 22.3% in the second quarter. Apis Capital Advisors LLC now owns 274,000 shares of the company’s stock worth $3,274,000 after purchasing an additional 50,000 shares in the last quarter. Magnetar Financial LLC bought a new position in Cellebrite DI in the 2nd quarter worth approximately $143,000. Finally, Sei Investments Co. increased its holdings in Cellebrite DI by 16.9% in the 2nd quarter. Sei Investments Co. now owns 141,644 shares of the company’s stock worth $1,693,000 after purchasing an additional 20,478 shares in the last quarter. Institutional investors own 45.88% of the company’s stock.

About Cellebrite DI

(Get free report)

Cellebrite DI Ltd. develops solutions for regulatory investigations in Europe, the Middle East, Africa, the Americas and Asia Pacific. The company’s DI solutions enable users to collect, review, analyze and manage digital data throughout the investigation cycle for regulatory investigations used in a variety of cases including child exploitation, homicide, counter-terrorism, border control, sexual crimes, human trafficking, corporate security, cryptocurrency and intellectual property theft.